Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals

Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical Co.Ltd, a technology-based company specializing in development and commercialization of niche generic drugs. 

Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will significantly boost Bora’s service offerings in key areas, such as formulation development, sterile ophthalmic, and niche manufacturing technologies. 

Bobby Sheng, CEO of Bora Pharmaceuticals, commented: “The acquisition of TWi Pharmaceuticals marks a huge milestone in Bora’s history as we become the largest pharmaceutical group by volume in Taiwan.

TWi has a long history of strong formulation development, as well as an impeccable quality track record.  As a result of acquiring TWi, Bora will be able to further expand on our capabilities as a full service CDMO. I’m looking forward to continuing our growth in this industry.”

TWi Pharmaceuticals USA operations will remain a separate entity and be able to take advantage of Bora’s existing large-scale production capacity and transfer the some of the commercial manufacturing of its generic and 505b2 drugs in the United States to the certain Bora sites. 

Sheng continued: “This will strengthen Bora’s position as a highly diversified global CDMO. Our expertise and capacity give us an edge over our competitors as we continue to expand our capabilities.”

Fuelled by the same mission and goal, Bora and TWi will strive to put Taiwan on the map as the centre of global pharmaceutical quality and demonstrate how Bora is an outstanding global supply chain partner.

Bora Pharmaceuticals also recently announced a large acquisition of an early-stage Biologics CDMO and a series of new investments as part of its five-year growth strategy. Bora covers the entire pharmaceutical supply chain from development through to commercial manufacture across a variety of dosage forms.

Find more information on its current services here.

ENDS

Media contact
Senior PR Executive, ramarketing
Danny McIver, daniel.mciver@ramarketingpr.com 

About Bora Pharmaceuticals:

Bora Pharmaceuticals is a premier international CGMP CDMO specializing in complex oral solid dosage, non-sterile liquids, nasal sprays, and semi-solids pharmaceutical Rx and OTC products for late-phase Clinical through Commercial manufacturing and packaging. Bora owns and operates three state-of-the-art CGMP manufacturing facilities (Taiwan and Canada) built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. Our TAA-compliant sites deliver to more than 100 markets around the world including the USA, Canada, EU, Southeast Asia, Middle East, and South and Central Americas. Bora handles high potency compounds, solvents, flammables, and IR/SR/ER release profile products. For more information visit: www.boracorpcdmo.com 

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems, as well as 505B2 drugs. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit  www.twipharma.com